San Jose, CA (Vocus/PRWEB) April 04, 2011Herpes Simplex Virus (HSV) is a commonly found human pathogen. Globally, an estimated 4.0 billion people are infected with Herpes Virus. The incidence rate of cold sores, caused by the HSV1 virus, is the second largest worldwide, trailing only behind common cold. About 79% of the US population is infected with HSV1, with about 25-35% of the adults enduring recurrent spate of cold sores. In all, close to 100 million outbreaks of cold sores occur each year in the US. Meanwhile, Genital herpes, caused by HSV-2, is one of the most common sexually transmitted diseases in the US. The rate of occurrence of genital herpes varies across different countries in developing regions. Certain African nations dealing with HIV epidemic are experiencing a high prevalence of HSV-2 infection.
Treatment-wise, there is no drug presently available in the market that can permanently cure herpes infection. However, various anti-viral therapies are available to alleviate painful symptoms of the infection. Present therapies for HSP infection include nucleoside analogs - acyclovir, and other related drugs. These drugs act by stalling the synthesis of viral DNA. Major drugs available in the market include Valtrex, Zovirax, Famvir, Abreva, Denavir, and Vistide. However, these drugs are known to cause drug related toxicity as a result of their interference with the natural metabolism of the human body. Also, with the virus subsequently developing resistance against the existing batch of anti-virals, the need for innovative therapies for the treatment of herpes simplex infection, and the search for novel antiviral drugs continues. This, therefore, presents a huge potential for the growth of herpes simplex therapeutics market in future. The introduction of HSV vaccines also presents new avenues for the treatment of HSV infection.
The HSV therapeutic market comprises drugs that are used for treating outbreaks and symptoms of herpes. These include drugs such as Acyclovir and valacyclovir, sold under Zovirax and Valtrex brands by GlaxoSmithKline. Acyclovir and valacyclovir are also available in generic variants, as the respective original drugs lost their patent protection. Promising drugs in the area of HSV treatment include Nanoviricides. These drugs have a distinct action mechanism when compared to existing drugs, which bodes the emergence of a potentially robust drug for treating HSV.
The US represents the largest regional market for Herpes Simplex Virus treatment worldwide, as stated by the new market research report on Herpes Simplex Virus Treatment. However, growth in the market would be led by US, which is projected to be the fastest growing regional market during the analysis period. Rest of World is projected to post a compounded annual growth rate of close to 6.9% during the analysis period.
Major players profiled in the report include Agenus Inc., AiCuris GmbH & Co.KG, Astellas Pharma Inc., BioVex, Clinigen Group, Cytogenix Inc., GlaxoSmithKline Plc., Lumavita AG, NanoBio Corporation, NanoViricides Inc., Novartis International AG, Sanofi-Aventis, Sinclair Pharma Plc., Starpharma Holdings Limited, Vical, Genocea Biosciences, among others.
The research report titled "Herpes Simplex Virus Treatment: A Global Strategic Business Report" announced by Global Industry Analysts Inc., provides a comprehensive review of the Herpes Simplex Virus treatment, current market trends, key growth drivers, the available treatment, overview of major drugs, insight into current leading and pipeline drugs, recent product approvals, recent industry activity, and profiles of major/niche global as well as regional market participants. The report provides annual sales estimates and projections for Herpes Simplex Virus treatment for the years 2009 through 2017 for the following geographic markets - US, Europe, and Rest of World. Also, a six-year (2003-2008) historic analysis is provided for additional perspective.
For more details about this comprehensive market research report, please visit -www.strategyr.com/Herpes_Simplex_Virus_Treatment_Market_Report.asp
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 800 people worldwide and publishes more than 1200 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Web Site: www.StrategyR.com/